1. Home
  2. TENX vs PNI Comparison

TENX vs PNI Comparison

Compare TENX & PNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$2.13

Market Cap

71.1M

Sector

Health Care

ML Signal

N/A

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

N/A

Current Price

$6.83

Market Cap

76.8M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
PNI
Founded
1967
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
71.1M
76.8M
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
PNI
Price
$2.13
$6.83
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
9.0M
64.5K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
N/A
4.76%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$6.55
52 Week High
$19.40
$7.20

Technical Indicators

Market Signals
Indicator
TENX
PNI
Relative Strength Index (RSI) 23.92 38.26
Support Level $1.31 $6.77
Resistance Level $14.15 $7.07
Average True Range (ATR) 0.20 0.04
MACD 0.17 -0.00
Stochastic Oscillator 75.00 11.11

Price Performance

Historical Comparison
TENX
PNI

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.

Share on Social Networks: